This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Life-threatening complications of infective endocarditis (IE,) are heart failure, uncontrolled infection and embolic events (EE), which pose significant morbidity and mortality risks. Depending on the location and severity of the embolism, the embolic risk can either escalate or alternatively, complicate and delay cardiac surgery.
(MedPage Today) -- Mortality rates were high among patients with high-risk pulmonary embolism (PE), with the worst outcomes in those with hemodynamic collapse, according to a retrospective analysis of the Pulmonary Embolism Response Team (PERT.
Findings from the first international randomized controlled trial to compare patient outcomes following treatment with large-bore mechanical thrombectomy (LBMT) versus catheter-directed thrombolysis (CDT) for intermediate-risk pulmonary embolism (PE) show that LBMT is superior with respect to the hierarchically-tested aggregated outcome of all-cause (..)
Some of the late-breaking topics that will be covered include transcatheter aortic valve replacement (TAVR), peripheral artery disease (PAD), and pulmonary embolism (PE): Impact of Age on Procedural Timing for Asymptomatic Severe Aortic Stenosis: Results from the Early TAVR Trial The PERFORMANCE II Trial: A Prospective Multicenter Single Arm Investigation (..)
BACKGROUND:Prior clinical trials have demonstrated the efficacy of ultrasound-facilitated catheter-directed thrombolysis (USCDT) for the treatment of acute intermediate-risk pulmonary embolism (PE) using reduced thrombolytic doses and shorter infusion durations.
In this case report, we demonstrated that thrombus aspiration and in situ thrombolysis through the Guidezilla GEC are applicable to patients with PE in whom systemic thrombolysis is contraindicated, resulting in successful reperfusion and positive clinical outcomes.
Background Pulmonary embolism is a condition of right cardiac dysfunction due to pulmonary circulation obstruction. Malignant tumor-induced pulmonary embolism, which has a poor therapeutic outcome and a significant impact on hemodynamics, is the cause of sudden death in patients with malignant tumors.
This Best Case Ever elucidates the practical challenges of working up pregnant patients in the ED with a suspicion of pulmonary embolism. Since this recording, the first ever multi-center prospective outcome study looking at the pulmonary embolism workup in pregnancy was published in the Annals of Internal Medicine.
patients to receive either the Amulet or Watchman and found that both devices had similar five year clinical outcomes, although Amulet held an edge in a couple key categories. The Amulet and Watchman devices were nearly tied for the studys composite rate of ischemic stroke or systemic embolism after five years (7.4%
After preoperative evaluation, coil embolization was successfully performed to treat the pseudoaneurysm, resulting in a satisfactory outcome at the 1-year follow-up.ConclusionCoil embolization serves as an effective treatment option for ascending aortic pseudoaneurysm in BD when open surgical repair and stent graft placement are unsuitable.
However, conventional surgical and transcatheter arterial embolization treatments are less effective. In the present case, a 76-year-old hypertensive woman was admitted with dizziness and diagnosed with an unruptured bronchial artery aneurysm, which was treated by transcatheter arterial embolization and aortic stent-graft.
We reported the feasibility and short-term outcomes of percutaneous transcatheter therapy with cerebral embolic protection. BACKGROUND:Surgery or fibrinolysis is the currently available evidence-based treatment for obstructive mechanical valve thrombus. The mean survival time free from death was 1101.48 (95% CI, 929.49–1273.47)
Massive pulmonary embolism (MPE) carries significant 30-day mortality and is characterized by acute right ventricular failure, hypotension, and hypoxia, leading to cardiovascular collapse and cardiac arrest. Considerable heterogeneity in studies is a significant weakness of the available literature.
Common embolism sites include the brain, spleen, kidneys, lungs, and intestines. Additionally, acute heart failure (AHF) can occur in up to 40% of cases, and its presence can impact the clinical outcomes of patients with IE. Cardiogenic shock (CGS) is often more likely to occur after AHF has taken place.
According to researchers, complications related to the embolization procedure were low, and neurological function was comparable to those without embolization. The primary outcome was how frequently there was reaccumulation of blood (a recurrence) that required surgical drainage within 90 days. of those who had surgery alone.
BACKGROUND:The aim of this study was to examine the impact of early versus delayed catheter-based therapies (CBTs) on clinical outcomes in patients with acute intermediate-risk pulmonary embolism (PE).METHODS:This Secondary outcomes included a composite of 30-day mortality, resuscitated cardiac arrest, and hemodynamic instability.
BackgroundWe aimed to reevaluate randomized controlled trial data on outcomes of cerebral embolic protection device use during transcatheter aortic valve implantation. Primary outcomes included all stroke, disabling stroke, and allcause mortality.
Aims Perioperative stroke remains a devastating complication after transcatheter aortic valve implantation (TAVI), and using a cerebral embolic protection device (CEPD) during TAVI may reduce the occurrence of stroke according to some studies.
Notably, acute massive pulmonary embolism (PE) with bilateral atrial thrombosis is an exceptional occurrence in CAPS. Acute pulmonary embolism (PE) is a common cardiovascular disease that progresses rapidly and has a high mortality rate. It primarily affects small vessels, seldom impacting large vessels.
Introduction:Middle meningeal artery embolization for chronic subdural hematomas is a promising treatment either as an adjuvant to surgical evacuation of the hematoma or as a primary treatment modality. A total of 67 patients (42%) were treated with particles and 93(58%) with liquid embolic agents. mm, p<0.59).Conclusions:The
Objectives The use of cerebral embolic protection (CEP) during transcatheter aortic valve implantation (TAVI) has been studied in several randomised trials. The primary outcome was the risk of disabling stroke. The minimal clinically important difference was determined at 1.1% ARD, per expert consensus (NNT 91).
Middle meningeal artery (MMA) embolization is being utilized more frequently as adjunctive and primary treatment. Here, we present the outcomes of this technique with different embolic agents in our patient population.IRB approval was obtained for this study. Vulnerable populations were excluded. Mean age was 73 years.
Chronic Thromboembolic Pulmonary Hypertension (CTEPH) is a severe and complex condition that evolves from unresolved pulmonary embolism, leading to fibrotic obstruction of pulmonary arteries, pulmonary hypertension, and potential right heart failure.
We aimed to do a meta-analysis comparing clipping with coil embolization for treatment of SAH in elderly people.Methods:We systematically searched Pubmed, Embase and Cochrane databases for studies that compared clipping with coiling for treatment of patients 60 years old with SAH.
Despite these excellent bleeding results, AZALEA-TIMI 71s stroke outcomes were not strong enough to sway researchers one way or another due to the studys early termination and small sample size (28 patients had a stroke or systemic embolism). per 100 person-years vs. 0.83).
a powerful and advanced mechanical thrombectomy system for the removal of venous thrombus and the treatment of pulmonary embolism (PE), effectively completing Penumbras VTE platform. Penumbras continuous advancements provide a comprehensive portfolio for physicians to treat a wider range of patients and improve patient outcomes.
Disambiguating embolism etiology is important to improve treatment efficacy and reduce recurrent events. Additionally, the embolus source-destination likelihood mapping provides detailed quantitative insights on the embolism etiology in these stroke patients. Stroke, Volume 56, Issue Suppl_1 , Page ATP388-ATP388, February 1, 2025.
The purpose of this study was to compare the outcomes of EVT for ICAD with those of cardiogenic cerebral embolism (CE) based on real-world data from a multicenter, prospective registry study (K-NET registry) involving 40 centers in Japan.Methods:The K-NET study enrolled 3187 EVTs in 2018-2021, of which 358 (11%) were ICAD and 1870 (59%) were CE.
Additionally, multivariable logistic regression models were applied to compare the secondary outcome of clinically relevant non-major bleeding (CRNMB) between the two groups.Results:The study included 2,003 AF patients, divided into two groups: 318 patients (15.9%) with a history of prior SSE and 1,685 patients (84.1%) without.
Middle meningeal artery embolization (MMAE) is a promising minimally invasive alternative with an estimated surgical recurrence rate of 6.8% Primary outcome is defined as the proportion of patients that require rescue surgery or die within 180 days. for standalone MMAE and combined MMAE and surgery respectively.
BackgroundCerebral embolic protection devices (CEPD) capture embolic material in an attempt to reduce ischemic brain injury during transcatheter aortic valve replacement. Primary clinical outcome was all‐cause stroke. Secondary clinical outcomes were disabling stroke and all‐cause mortality.
Publication date: Available online 28 October 2024 Source: The American Journal of Cardiology Author(s): Aryan Mehta, Mridul Bansal, Siddhant Passey, Saurabh Joshi, Carlos L Alviar, Jason N Katz, J Dawn Abbott, Saraschandra Vallabhajosyula
Publication date: Available online 31 December 2024 Source: The American Journal of Cardiology Author(s): Aryan Mehta, Mridul Bansal, Abhishek Singh, Ritika Kompella, Anindita Chanda, Chirag Mehta, Christopher J Mullin, J Dawn Abbott, Saraschandra Vallabhajosyula
Background:The use of oral anticoagulation (OAC) for stroke prevention in embolic stroke of undetermined source (ESUS) is hypothesized to be beneficial over conventional antiplatelet use. The primary outcome was stroke recurrence, and the safety outcome was major bleeding. A random-effects model was used for the analyses.
A new Intelligent thrombo-suction catheter system , is being introduced for treatment of acute pulmonary embolism.This device regulates the force with which thrombus is sucked , with less injury and bleeding and better outcomes. Human studies & Evidence The experience from this device was presented in ESC 2024 London.
The inflow aneurysms were accessed and embolized with coils using a second microcatheter prior to AVM embolization. Extensive but partial filling of the AVM was noted anteriorly but full embolization of the posterior aspect of the nidus was not achieved. Onyx‐18 was then injected into the main AVM pedicle under a blank roadmap.
Previous studies have noted that ICAD-related LVOs, compared to embolic occlusions, have longer procedural times and lower successful reperfusion rates. However, clinical outcomes remain similar. Patient outcomes at 3 months were assessed using modified Rankin Scale (mRS) scores, defining devastating outcomes as mRS 5-6.
What are the in-hospital and readmission outcomes in patients with intermediate-risk or high-risk pulmonary embolism (PE) treated with versus without catheter-based therapies (CBTs) in a large retrospective registry?
This critical information empowers physicians to select the most suitable endovascular therapeutic approach, thereby mitigating complications, avoiding embolization, and enhancing long-term treatment outcomes.
BackgroundThrombocytopenia is often associated with adverse outcomes in patients with atrial fibrillation. Compared to no thrombocytopenia, atrial fibrillation patients combined with thrombocytopenia have a significant risk reduction of ischemic stroke/systemic embolism [OR: 0.79, 95% CI: (0.69, 0.91); P < 0.01].
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content